Breast Density and Mammography: When White Hides White

Key Takeaways:

• Women whose mammograms showed density in 75 percent or more of the breast had 4.7 times the breast cancer risk of women with density in less than 10 percent, and nearly 18 times the risk of a cancer surfacing within a year after a normal screen.
• In a study of more than 329,000 women, the sensitivity of screening mammography fell from 87 percent in almost entirely fatty breasts to about 63 percent in extremely dense breasts.
• In the randomized DENSE trial, offering supplemental MRI to women with extremely dense breasts and a normal mammogram cut interval cancers in half, from 5.0 to 2.5 per 1,000 screenings, at the cost of about 80 false positives per 1,000 MRIs.

A mammogram is a picture of contrast. Fat lets x-rays pass and shows up dark gray, while fibroglandular tissue, the milk ducts, lobules, and supporting connective tissue, absorbs more of the beam and shows up white. A tumor is dense, too, so it also shows up white. In a breast made mostly of fat, a small cancer stands out like a pebble on dark sand. In a breast with abundant fibroglandular tissue, the same cancer can sit inside a field of white and simply disappear, the way a white hare vanishes against fresh snow. Radiologists describe this with four categories: almost entirely fatty, scattered fibroglandular density, heterogeneously dense, and extremely dense, and the last two are what reports mean by dense breasts. Breast density is common, it is not a disease, and it usually declines with age. But it matters in two separate ways, and many women scheduling a screening this month have never had either explained. The first is masking: dense tissue hides cancers. The second is that dense tissue is itself associated with a higher chance of developing breast cancer, not merely a harder time seeing it. More fibroglandular tissue means more of the epithelial and stromal cells from which breast cancers arise, and that elevated risk shows up even when cancers are found by screening, which is how researchers know it is not just an artifact of missed tumors.

The numbers behind both effects are substantial. In three nested case-control studies within screened populations, women whose baseline mammograms showed density in 75 percent or more of the breast had 4.7 times the breast cancer risk of women with density in less than 10 percent. The risk was elevated for cancers caught on screening, about 3.5-fold, and dramatically higher, nearly 18-fold, for interval cancers that surfaced within 12 months after a negative mammogram, which is the fingerprint of masking. The excess risk persisted for at least eight years. Among women younger than 56, about a quarter of all breast cancers, and half of the cancers found within a year of a negative screen, were attributable to density in at least half the mammogram. A large prospective study of more than 460,000 screening mammograms quantified the masking directly: adjusted sensitivity was 87 percent in almost entirely fatty breasts but only about 63 percent in extremely dense breasts, and specificity fell as well, meaning more callbacks. Because women were often never told their density, federal regulators acted. Under an updated Mammography Quality Standards Act rule, published in March 2023 and in force since September 10, 2024, every mammography report must give the clinician the breast’s density category, and the lay summary letter sent to the patient must state whether the breast tissue is dense or not dense, with standard language explaining that dense tissue can make cancer harder to find and raises risk, and that other imaging tests may help.

What should you do if your mammogram report says breast density is high?

First, keep getting mammograms. Density lowers their sensitivity but does not make them useless, and they remain the foundation of screening. The second step is a conversation about your overall risk, because density is one input alongside family history, genetics, prior biopsies, and age. Supplemental imaging can find cancers that mammography misses, and the evidence is real but comes with trade-offs. In a multicenter study of women with dense tissue at elevated risk, adding a single screening ultrasound to mammography detected about 4.2 additional cancers per 1,000 women, most of them small, invasive, and node-negative, but it also substantially increased false positives, and fewer than one in ten ultrasound-prompted biopsies found cancer. MRI is more sensitive still. In the randomized DENSE trial of more than 40,000 women with extremely dense breasts and a normal mammogram, being invited to supplemental MRI halved interval cancers over a two-year screening round, and MRI found 16.5 cancers per 1,000 screenings among women who had it. Yet about 80 of every 1,000 MRI screens produced a false-positive result, only 59 percent of invited women accepted, and the trial measured interval cancers, not deaths. Supplemental screening therefore remains a personal decision rather than a universal rule, shaped by your overall risk, your tolerance for callbacks and biopsies, and access and cost. Knowing your density, and what it can and cannot tell you, is what makes that decision possible.

References:

1. Boyd, N. F., Guo, H., Martin, L. J., Sun, L., Stone, J., Fishell, E., et al. (2007). Mammographic density and the risk and detection of breast cancer. New England Journal of Medicine, 356(3), 227-236.
2. Carney, P. A., Miglioretti, D. L., Yankaskas, B. C., Kerlikowske, K., Rosenberg, R., Rutter, C. M., et al. (2003). Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Annals of Internal Medicine, 138(3), 168-175.
3. U.S. Food and Drug Administration. (2023, March 10). Mammography Quality Standards Act; amendments to part 900 regulations (final rule; compliance date September 10, 2024). Federal Register, 88, 14528.
4. Berg, W. A., Blume, J. D., Cormack, J. B., Mendelson, E. B., Lehrer, D., Böhm-Vélez, M., et al. (2008). Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA, 299(18), 2151-2163.
5. Bakker, M. F., de Lange, S. V., Pijnappel, R. M., Mann, R. M., Peeters, P. H. M., Monninkhof, E. M., et al. (2019). Supplemental MRI screening for women with extremely dense breast tissue. New England Journal of Medicine, 381(22), 2091-2102.